Saltar para: Posts [1], Pesquisa e Arquivos [2]


Noticias de Crohn - Copy.png

Resumo na língua original:

(...)

 

There is no known cure for this disease. Various therapies help reduce the symptoms and allow people to function better. Crohn’s disease impacts a great number of young people – usually those in their twenties. Life expectancy with Crohn’s disease should not be a concern. This disease doesn’t directly affect life expectancy.

 

There have been a lot of advances in the diagnosis and treatment of Crohn’s. What people do have to consider though is Crohn’s disease life expectancy without treatment. In the 1950s, a severe attack of Crohn’s disease meant a 30 to 60 percent risk of death, but that risk is now three percent when a patient follows a proper treatment plan. These treatments include everything from prescription medications to natural treatments, diet, exercise, as well as stress control techniques.

 

(...)

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 11:00

Noticias de Crohn - Copy.png

Resumo na língua original:

French biotech, Enterome, has developed an oral, microbiome therapy to combat Crohn’s disease. Many researchers are turning to the microbiome, as they believe the field could hold the key to human health. The candidate, EB8018 has demonstrated good tolerability at a range of doses and that it remains in the gut during a Phase I study. The company is now in the process of initiating a Phase Ib trial to investigate the drug’s safety, pharmacokinetics and efficacy that would support a Phase II study planned for next year.

 

 

(...)

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 11:00

Noticias de Crohn - Copy.png

Resumo na língua original:

Celgene Corporation is giving up on GED-0301 as a Crohn’s disease therapy, but will continue to evaluate its ability to treat ulcerative colitis.

 

It ended its Phase 3 REVOLVE clinical trial (NCT02596893) and its SUSTAIN extension trial (NCT02641392) of GED-0301 as a potential Crohn’s treatment after an independent trial monitoring board recommended the discontinuations. The board had reviewed the therapy’s benefits and risks, and the implication of its recommendation was that GED-0301 failed to generate enough benefits.

 

(...)

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 11:00

Noticias de Crohn - Copy.png

Resumo na língua original:

A growing body of clinical evidence shows that transplantation of a patient's own mesenchymal stem cells (MSCs) to achieve a cure and prevent recurrent of Crohn's disease-related fistula can be a safe and effective addition to surgery. A comprehensive review of the latest studies of MSC transplantation for Crohn's fistula and a comparison of MSC versus hematopoietic stem cell (HSC) transplantation is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website until October 14, 2017.

 

(...)

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 17:17

Noticias de Crohn - Copy.png

Assim como ontem, mais um meddicamento biossimilar aprovado, desta vez na Europa .

 

Resumo na língua original:

The European Commission has approved Imraldi, an adalimumab biosimilar referencing AbbVie’s Humira — making the medication available to treat the same therapeutic indications as Humira, including Crohn’s disease, pediatric Crohn’s disease and ulcerative colitis.

The Aug. 24 decision followed a positive recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use, released in June.

 

(...)

 

Imraldi will be available for any patient older than 6 years of age with moderate-to-severe active Crohn’s disease who have not responded to corticosteroid or immunosuppressant treatment regimens, or who cannot tolerate standard-of-care therapies. Imraldi will also be approved to treat adult patients moderate-to-severe ulcerative colitis who do not respond to first-line of therapy with corticosteroids and Purinethol (6-mercaptopurine) or Azasan (azathioprine), who are intolerant, or who have medical contraindications for such treatments.

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 17:43

Noticias de Crohn - Copy.png

Esta notícia vem ao encontro de outra que publiquei aqui recentemente. O principal beneficio da aprovação destes medicamentos é o seu custo, com o aumento da concorrência neste mercado veremos os preços a ficar mais competitivos e isso é benéfico para o sistema nacional de saúde e possivelmente para os doentes, se eventualmente estes medicamentos deixarem de ser comparticipados a 100% como acontece atualmente.

 

Resumo na língua original:

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim‘s Cyltezo— a biosimilar of Abbvie’s Humira (adalimumab) — to treat Crohn’s disease, ulcerative colitis and a host of other diseases ranging from rheumatoid arthritis to ankylosing spondylitis.

 

Cyltezo is the German company’s first FDA-approved biosimilar and “marks an important step towards our goal of providing new and more affordable treatment options to healthcare providers and patients,” Ivan Blanarik, senior vice-president and head of Boehringer Ingelheim’s therapeutic area biosimilars, said in a press release.

 

(...)

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 17:32

Noticias de Crohn - Copy.png

Resumo na língua original:

The independent Data and Safety Monitoring Board has unanimously recommended the continuation of the phase 3 MAP US study evaluating RHB-104, an investigative oral antibiotic therapy for Crohn’s disease, according to RedHill Biopharma, who remains blinded to the data.

 

RHB-104 is a “potentially groundbreaking” oral antibiotic combination therapy with intracellular, antimycobacterial and anti-inflammatory properties that targets Mycobacterium avium subspecies paratuberculosis (MAP), a bacterial infection and a suspected cause of Crohn’s disease, according to a press release.

 

(...)

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 17:28

Noticias de Crohn - Copy.png

Estou a partilhar esta notícia porque na verdade o que é descrito neste artigo é um dos meus maiores medos. Com os sitomas que estou habituado a ter com a doença de Crohn se - ou quando - tiver de facto uma doença grave como cancro do intestino não vou dar importâncias aos sintomas por pensar que é da DC. E só irei ao médico quando os sintomas se agravarem bastante, altura em que poderá ser tarde demais... 

 

Resumo na língua original:

As Hagger was diagnosed with Crohn’s disease aged 15, she put her symptoms down to a flare up of the inflammatory bowel disease and cut out gluten and dairy from her diet, “but nothing worked”.

 

Hagger struggled for three months before she asked her doctor for a colonoscopy which identified she had bowel cancer. She believes the procedure saved her life.

 

(...)

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 18:10

Noticias de Crohn - Copy.png

Infelizmente, segundo o artigo, este pigmento (E171) também é utilizado em pastas de dentes. Portanto pessoas que tenham DII devem evitar consumir alimentos com este "ingrediente".

 

Resumo na língua original:

Titanium dioxide nanoparticles, which are increasingly used in food products as well as in cosmetics and some medicines, might increase inflammation of the digestive system, new research suggests.

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 17:19

Noticias de Crohn - Copy.png

A parte mais intere$$ante deste artigo é que o medicamento vai ser comercializado com um preço 35% inferior ao do Remicade! 

 

Resumo na língua original:

New drug Renflexis (infliximab-abda), a therapy for ulcerative colitis and Crohn’s disease, is being launched in the U.S., South Korea’s Samsung Bioepis recently announced.

Renflexis is a biosimilar of the anti-inflammatory drug Remicade (infliximab) and is being commercialized in the U.S. by Merck.

 

(...)

 

Renflexis will be introduced in the U.S. at a wholesale acquisition cost of $753.39, which is 35 percent less than Remicade, according to Samsung Bioepis. This price does not include potential additional discounts.

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 17:00


Pesquisar

  Pesquisar no Blog

Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.



Posts mais comentados




subscrever feeds